20.500.12556/DiRROS-31214 Tumor ablation emerging uses, challenges, and strategic implementation a green green paper by the network of expertise in cancer (jane-2), high tech medical resources, network on physical methods of tumor ablation The field of oncology has witnessed remarkable progress with the integration of high-tech innovations in tumor ablation. Tumor ablation therapies, such as radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation (Cryo), irreversible electroporation (IRE), and electrochemotherapy (ECT) have evolved beyond conventional boundaries, offering patients less invasive, highly targeted therapeutic options. Since it works across cancer histologies, tumor ablation is being integrated into cancer care at several levels. Tumor ablation is even considered curative in selected patients with small primary or secondary tumors, e.g. in the liver. Furthermore, it is central in treatment of oligometastatic disease or oligoprogression. Finally, ablation is widely used for symptomatic relief when tumors lead to symptoms affecting quality of life. Knowledge about ablative therapies and their inclusion at multidisciplinary team decision making enables effective and more personalized treatment for patients. This review synthesizes emerging applications of these therapies, focusing on artificial intelligence-driven personalization, robotic-assisted precision, and hybrid models combining ablation with systemic treatments, immunotherapy or targeted drug delivery. It also discusses the infrastructural, educational, regulatory, and ethical challenges that influence the clinical adoption of such treatments. Finally, the review presents strategic recommendations for integrating advanced ablation therapies into healthcare systems while ensuring equity, patient trust, and global accessibility. cancer ablation high-tech innovations emerging applications regulatory issues ethical issues onkologija true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2026-07-22 10:13:14 2026-07-22 10:13:14 2026-07-23 03:51:06 0000-00-00 00:00:00 2026 0 0 Soavtorji: Philippe L Pereira, Colin P Cantwell, Frédéric Deschamps, Anja Kocijancic, Nina Schmidt, Rok Dezman, Greta Chlebopasevienė, Andrei Roman, Maja Cemazar Gregor Sersa; str. 153-165 no. 2 Vol. 60 June 2026 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2026-06-01 616-006 1318-2099 10.2478/raon-2026-0030 284769795 https://reference-global.com/article/10.2478/raon-2026-0030 1 31ce8c1d-85a5-11f1-a226-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=48166 RAZ_Gehl_Julie_2026.pdf RAZ_Gehl_Julie_2026.pdf 1 B55743C4293ABD2A6249D6947B8F1CD3 488b2bb4a347136ff062f65ac5b38edbcb435b493dc91af5538d86ddbdf0c900 990a314d-85a5-11f1-a226-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=48167 Onkološki inštitut Ljubljana Društvo radiologije in onkologije 0 0 0